Development of optimized AAV3 serotype vectors: mechanism of high-efficiency transduction of human liver cancer cells
Cheng B, Ling C, Dai Y, Lu Y, Glushakova L, Gee S, McGoogan K, Aslanidi G, Park M, Stacpoole P, Siemann D, Liu C, Srivastava A, Ling C. Development of optimized AAV3 serotype vectors: mechanism of high-efficiency transduction of human liver cancer cells. Gene Therapy 2011, 19: 375-384. PMID: 21776025, PMCID: PMC3519243, DOI: 10.1038/gt.2011.105.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBreast NeoplasmsCarcinoma, HepatocellularCell Line, TumorDependovirusFemaleGenetic VectorsHumansLiver NeoplasmsMiceMutagenesis, Site-DirectedProteasome InhibitorsProtein Structure, TertiaryProto-Oncogene Proteins c-metTransduction, GeneticTransplantation, HeterologousTyrosineVirus IntegrationConceptsHigh-efficiency transductionAAV3 vectorsTransduction efficiencySerotype vectorsSurface-exposed tyrosinePotential gene therapyHuman hepatocyte growth factor receptorHuman liver cancer cellsGene therapyLiver cancer cellsTransgene expressionVector entryAAV3 capsidsDirect intratumoral injectionAAV3Tail vein injectionLiver tumor cellsIntratumoral injectionCancer cellsEfficiencyAdenoVectorIntracellular kinase domainVirus serotypes